Relationship between Pharmacokinetic Parameters and Occurrence of Adverse Events in Clinical Trials Performed in Europe and United States for an Angiotensin II Receptor Antagonist, Telmisartan-Reference-Cited by-同舟云学术

Relationship between Pharmacokinetic Parameters and Occurrence of Adverse Events in Clinical Trials Performed in Europe and United States for an Angiotensin II Receptor Antagonist, Telmisartan

Published:2004 Issue:1 Volume:19 Page:24-32
ISSN:1347-4367
Container-title:Drug Metabolism and Pharmacokinetics
language:en
Short-container-title:Drug Metabolism and Pharmacokinetics

Author:

Tatami Shinji,Sarashina Akiko,Yamamura Norio,Igarashi Takashi,Tanigawara Yusuke

Publisher

Japanese Society for the Study of Xenobiotics

Subject

Pharmacology (medical),Pharmaceutical Science,Pharmacology

Reference16 articles.

1. Pharmacological characterization of the novel nonpeptide angiotensin II receptor antagonist, BIBR 277;Wienen;Br. J. Pharmacol.,1993

2. A review on telmisartan: a novel, long-acting angiotensin II-receptor antagonist;Wienen;Cardiovasc. Drug Rev.,2000

3. Dose response and antihypertensive efficacy of the AT1 receptor antagonist telmisartan in patients with mild to moderate hypertension;Neutel;Adv. Ther.,1998

4. Dose response and safety of telmisartan in patients with mild to moderate hypertension;Smith;J. Clin. Pharmacol.,2000

5. Population pharmacokinetics of an angiotensin II receptor antagonist, telmisartan, in healthy volunteers and hypertensive patients;Tatami;Drug Metab. Pharmacokin.,2003

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A validated bioanalytical method for the simultaneous estimation of telmisartan and gallic acid in rat plasma samples by high‐performance thin‐layer chromatography–mass spectrometry: Application to an oral pharmacokinetic study;Biomedical Chromatography;2023-11-14

2. Don't Get Boxed In: Commentary on the Visual Inspection Practices to Assess Exposure-Response Relationships From Binary Clinical Variables;The Journal of Clinical Pharmacology;2012-12

3. Respiratory adverse event profiles in cystic fibrosis placebo subjects in short- and long-term inhaled therapy trials;Contemporary Clinical Trials;2006-12